Home / Business and Economy / Apnimed Eyes $608M Valuation in IPO Bid
Apnimed Eyes $608M Valuation in IPO Bid
27 Jul
Summary
- Apnimed is targeting a valuation up to $608 million.
- The company is seeking to raise up to $160 million.
- Shares are offered between $14 and $16 apiece.
Drug developer Apnimed is preparing for its initial public offering in the United States, with the company targeting a valuation of up to $608 million. This move signifies a significant step for the late-stage developer focused on sleep apnea treatments.
Apnimed aims to raise substantial capital through this IPO, seeking to secure as much as $160 million. The offering will consist of 10 million shares, with an anticipated price range of $14 to $16 per share. This information was disclosed in a regulatory filing submitted on Monday.
The company's focus on sleep apnea treatments positions it within a key area of medical need. The potential capital raised from the IPO is expected to fuel further development and expansion of its drug pipeline.
